Key result
In silico analysis suggests Zhigancao decoction may treat CHF via 10 compounds targeting MMP9.
Why the study?
Zhigancao decoction has shown therapeutic potential in CHF, but the molecular mechanisms underlying its pharmacological effects remain incompletely understood.
In silico analysis suggests Zhigancao decoction may treat chronic heart failure by targeting MMP9 and modulating oxidative stress and immune-related pathways.
Does not support clinical use of Zhigancao decoction; leaves open MMP9 targeting in chronic heart failure pending validation.
BACKGROUND: Zhigancao decoction has shown therapeutic potential in the management of chronic heart failure (CHF); however, the molecular mechanisms underlying its pharmacological effects remain incompletely understood. This study aimed to investigate its potential mechanisms, with a particular focus on oxidative stress-related pathways. METHODS: The chemical profile of Zhigancao decoction was characterized by LC-MS/MS, and putative targets were predicted using SwissTargetPrediction. A protein-protein interaction (PPI) network was established using the STRING database and Cytoscape software, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Differentially expressed genes from two GEO datasets (GSE9128 and GSE84796) were integrated with reactive oxygen species (ROS)-related genes to identify candidate targets. Network pharmacology and molecular docking were subsequently performed to investigate compound-target interactions. RESULTS: A total of 66 chemical constituents and 818 putative targets were characterized and collected, respectively. Among these targets, MMP9 emerged as a central candidate associated with the therapeutic effects of Zhigancao decoction. GO and KEGG enrichment analyses demonstrated that the core targets were significantly enriched in oxidative stress-related pathways, inflammatory signaling cascades, and cell fate regulatory pathways. Computational deconvolution of bulk transcriptomic data suggested marked alterations in the estimated immune cell composition of the CHF microenvironment. Network pharmacology analysis further indicated that multiple chemical constituents of Zhigancao decoction converge on MMP9 and its associated pathways. Molecular docking analysis demonstrated favorable binding affinities between 10 representative compounds and MMP9, with binding energies below -7.0 kcal/mol. CONCLUSIONS: In silico predictions suggest that Zhigancao decoction may exert potential therapeutic effects against CHF through computationally predicted targeting of MMP9 and associated oxidative stress- and immune-related pathways. These computational findings provide a theoretical foundation for future experimental investigations into the mechanisms of Zhigancao decoction in CHF, though clinical application would require confirmation through rigorous in vivo and clinical studies.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied Chronic heart failure. Zhigancao decoction was evaluated on Putative targets, pathway enrichment, and binding affinities. In silico analysis suggests Zhigancao decoction may exert therapeutic effects against chronic heart failure by targeting MMP9, with 10 compounds showing binding energies below -7.0 kcal/mol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: